Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled,
single/multiple dosing, dose escalation clinical trial with open-labelled food effect study
of single dose to investigate the safety, tolerability and pharmacokinetics of DA-6886 after
oral administration in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd. Dong-A ST Co., Ltd.